Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 2, 2003, Pages 594-600

  Marcelin, Anne Geneviève ^a   Lamotte, Claire ^b   Delaugerre, Constance ^a   Ktorza, Nadine ^a   Mohand, Hocine Ait ^a   Cacace, Raquel ^a   Bonmarchand, Manuela ^a   Wirden, Marc ^a   Simon, Anne ^a   Bossi, Philippe ^a   Bricaire, François ^a   Costagliola, Dominique ^a   Katlama, Christine ^a   Peytavin, Gilles ^b   Calvez, Vincent ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; DIDANOSINE; HYDROXYUREA; LAMIVUDINE; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; DOSE RESPONSE; EXPERIENCE; FEMALE; GENE MUTATION; GENETIC RESISTANCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PREDICTION; PRIORITY JOURNAL; PROTEINASE INHIBITION; SCORING SYSTEM; TREATMENT FAILURE; VIRUS INFECTION; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION;

ADULT; CARBAMATES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RITONAVIR; SULFONAMIDES; VIRAL LOAD;

EID: 0037308542     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.2.594-600.2003     Document Type: Article

References (19)

1. Calvez, V., D. Costagliola, D. Descamps, A. Yvon, G. Collin, A. Cécile, C. Delaugerre, F. Damond, A. G. Marcelin, S. Matheron, A. Simon, M. A. Valantin, C. Katlama, and F. Brun-Vezinet. 2002. Impact of stavudine phenotype and thymidine analog mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial. Antivir. Ther. 7:211-218.
2. Delfraissy, J. F. 2000. Prise en charge thérapeutique des personnes infectées par le VIH. Médecine-Sciences, Paris, France.
3. Duval, X., C. Lamotte, E. Race, D. Descamps, F. Damond, F. Clavel, C. Leport, G. Peytavin, and J. L. Vilde. 2002. Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir. Antimicrob. Agents Chemother. 46:570-574.
4. Dural, X., V. Le Moing, C. Longuet, C. Leport, J. L. Vilde, C. Lamotte, G. Peytavin, and R. Farinotti. 2000 Efavirenz-induced decrease in plasma amprenavir levels in human immunodeficiency virus-infected patients and correction by ritonavir. Antimicrob. Agents Chemother. 44:2593.
5. Falloon, J., S. Piscitelli, S. Vogel, B. Sadler, H. Mitsuya, M. F. Kavlick, K. Yoshimura, M. Rogers, S. LaFon, D. J. Manion, H. C. Lane, and H. Masur. 2000. Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity. Clin. Infect. Dis. 30:313-318.
6. Hirsch, M. S., F. Brun-Vezinet, R. T. D'Aquila, S. M. Hammer, V. A. Johnson, D. R. Kuritzkes, C. Loveday, J. W. Mellors, B. Clotet, B. Conway, L. M. Demeter, S. Vella, D. M. Jacobsen, and D. D. Richman. 2000. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society - USA Panel. JAMA 283:2417-2426.
7. Jung, M., H. Agut, D. Candotti, D. Ingrand, C. Katlama, and J. Huraux. 1992. Susceptibility of HIV-1 isolates to zidovudine: correlation between widely applicable culture test and PCR analysis. J. Acquit. Immune Defic. Syndr. 5:359-364.
8. Kempf, D. J., K. C. Marsh, G. Kumar, A. D. Rodrigues, J. F. Denissen, E. McDonald, M. J. Kukulka, A. Hsu, G. R. Granneman, P. A. Baroldi, E. Sun, D. Pizzuti, J. J. Plattner, D. W. Norbeck, and J. M. Leonard. 1997. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob. Agents Chemother. 41:654-660.
9. Larder, B. A., P. Kellam, and S. D. Kemp. 1991. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS 5:137-144.
10. Li, T. S., R. Tubiana, C. Katlama, V. Calvez, H. Ait Mohand, and B. Autran. 1998. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 351:1682-1686.
11. Marsh, K. C., E. Eiden, and E. McDonald. 1997. Determination of ritonavir, a new HIV protease inhibitor, in biological samples using reversed-phase high-performance liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl. 704:307-313.
12. Mocroft, A., S. Vella, T, L. Benfield, A. Chiesi, V. Miller, P. Gargalianos, A. d'Arminio Monforte, I. Yust, J. N. Bruun, A. N. Phillips, J. D. Lundgren, et al. 1998. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 352:1725-1730.
13. Nijhuis, M., C. A. Boucher, P. Schipper, T. Leitner, R. Schuurman, and J. Albert. 1998. Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy. Proc. Natl. Acad. Sci. USA 95:14441-14446.
14. Sadler, B. M., C. Gillotin, Y. Lou, and D. S. Stein. 2001. Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing. Antimicrob. Agents Chemother. 45:30-37.
15. Sadler, B. M., C. D. Hanson, G. E. Chittick, W. T. Symonds, and N. S. Roskell. 1999. Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults. Antimicrob. Agents Chemother. 43:1686-1692.
16. Sadler, B. M., P. J. Piliero, S. L. Preston, P. P. Lloyd, Y. Lou, and D. S. Stein. 2001. Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers. AIDS 15:1009-1018.
17. Schmidt, B., K. Korn, B. Moschik, C. Paatz, K. Uberla, and H. Walter. 2000. Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors. Antimicrob. Agents Chemother. 44:3213-3216.
18. Tisdale, M., R. Myers, S. Randall, M. Maguire, M. Ait-Khaled, R. Elston, and W. Snowden. 2000. Evolution of resistance to the protease inhibitor amprenavir in vitro and in clinical studies. Clin. Drug Investig. 20:267-285.
19. van Heeswijk, R. P., A. I. Veldkamp, R. M. Hoetelmans, J. W. Mulder, G. Schreij, A. Hsu, J. M. Lange, J. H. Beijnen, and P. L. Meenhorst. 1999. The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals. AIDS 13:F95-F99.